The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions.

Maria Mastrogiannaki, Pavle Matak, Carole Peyssonnaux

To cite this version:


HAL Id: inserm-01068507
http://www.hal.inserm.fr/inserm-01068507
Submitted on 25 Sep 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions

Maria Mastrogiannaki,1-3 Pavle Matak,1-3 and Carole Peyssonnaux1-3

1Institut National de la Santé et de la Recherche Médicale (INSERM), U1016, Institut Cochin, Paris, France; 2Centre National de la Recherche Scientifique, UMR8104, Paris, France; and 3Université Paris Descartes, Sorbonne Paris Cité, Paris, France

Although earlier, seminal studies demonstrated that the gut per se has the intrinsic ability to regulate the rates of iron absorption, the spotlight in the past decade has been placed on the systemic regulation of iron homeostasis by the hepatic hormone hepcidin and the molecular mechanisms that regulate its expression. Recently, however, attention has returned to the gut based on the finding that hypoxia inducible factor-2 (HIF-2α) regulates the expression of key genes that contribute to iron absorption. Here we review the current understanding of the molecular mechanisms that regulate iron homeostasis in the gut by focusing on the role of HIF-2 under physiological steady-state conditions and in the pathogenesis of iron-related diseases. We also discuss implications for adapting HIF-2–based therapeutic strategies in iron-related pathological conditions. (Blood. 2013;122(6):885-892)
L (FtL) subunits. FtH possesses ferroxidase activity and has been shown, in addition to its iron storage function, to play an active role in iron export.16

Accordingly, Fpn deletion in the murine intestine results in enterocyte iron overload and neonatal lethality.17 FPN exports Fe2⁺; the release of iron from FPN is coupled to the actions of copper-dependent ferroxidases, primarily the transmembrane protein hephaestin (HEPH).18 HEPH catalyzes the oxidation of Fe⁺² to Fe⁺³, which is subsequently bound to transferrin. Disruption of HEPH activity (eg, by copper deficiency or mutation, as in the sex-linked anemia mouse) results in iron sequestration in enterocytes, confirming its key role in iron export across the enterocyte basolateral membrane.19

Free heme is highly insoluble due to its hydrophobic porphyrin ring. However, heme can be complexed to a number of chelators (including arginate and albumin) and preferentially absorbed in duodenum as the intestinal pH 5.5 to 6 favors its solubility.20 Heme carrier protein 1 has been proposed as an intestinal heme transporter, but in vivo studies indicate that heme carrier protein 1 functions predominantly as a folate transporter.21 Therefore, the mechanism of heme uptake by enterocytes remains unresolved. HRG-1 is another heme transporter,22 for which an essential role for macrophage heme-iron recycling has been recently demonstrated.23 HRG-1 may potentially function as a heme transporter in the intestine. Heme is catabolized by heme-oxygenase into Fe⁺² bilirubin and carbon monoxide. Feline leukemia virus subgroup C cellular receptor C cellular receptor is a transmembrane heme exporter that plays a key role in erythropoiesis by exporting excess heme from maturing erythroblasts in humans.24 Feline leukemia virus subgroup C cellular receptor is also abundantly expressed in the duodenum, but its specific role in heme export from enterocytes has not been addressed.

Systemic vs local regulation of iron absorption in the gut

Iron absorption is increased under conditions of iron deficiency, increased erythropoietic drive, and hypoxia and is decreased by iron loading and inflammation. Expression of the key proteins involved in iron absorption is controlled at multiple levels: transcriptional, posttranscriptional, and posttranslational. The different steps of the iron absorption process may be subject to distinct cell-autonomous mechanisms and/or systemic regulation by hepcidin.

The majority of the body’s daily iron consumption is used to meet the needs of erythropoiesis. In settings of increased erythropoietic demand, intestinal iron absorption increases to meet the marrow’s needs for additional iron. Increased erythropoietic activity in the bone marrow is observed in different forms of anemia ranging from iron-deficiency anemia to hereditary forms characterized by ineffective erythropoiesis, such as β-thalassemia. Prolonged exposure to a hypoxic environment in humans, as well as experimental hypoxia and anemia induced by phlebotomy/hemolysis in mouse models, is also characterized by an increased erythropoietic demand and results in an increase in iron absorption rates.25-27

Systemic regulation of iron absorption by hepcidin

Increased iron absorption correlates with elevated expression of DMT1, DCYTB, and FPN at the messenger RNA (mRNA) and protein level.7,11,28,29 Hepatic hepcidin expression is inversely correlated with the duodenal expression of iron transporters and iron absorption rates in various mouse models of hepcidin overexpression and deficiency.30-32 The established view is that plasma hepcidin inhibits iron efflux into plasma by directly binding to and thereby inducing the degradation of FPN, which is located on enterocytes and macrophages. However, data on the precise molecular actions of hepcidin on FPN in the gut are less clear.29,33-35

Some reports have suggested that hepcidin also may reduce iron absorption by decreasing the expression of enterocyte DMT1, either at the transcription level34 or through ubiquitin-dependent proteasomal degradation.35 The Nedd4 interacting protein 1 (NDFP1) and 2 (NDFP2) adaptor proteins have been reported to regulate DMT1 in vitro via ubiquitination by WW domain containing E3 ubiquitin protein ligase 2 (WWP2) and neural precursor cell expressed developmentally down-regulated 4-like E3 ubiquitin protein ligase (NEDD4L or NEDD4-2) in Chinese hamster ovary cells.36 The involvement of this NDFIPs-WWP2 pathway in the hepcidin-mediated degradation of DMT1 remains to be demonstrated.

Local regulation of iron absorption in enterocytes

Although it is widely recognized that low liver hepcidin expression contributes to the upregulated expression of iron transporters during iron deficiency, in vitro evidence has suggested that the upregulated expression of iron transporters that occurs following exposure to desferroxamine, an iron chelator, occurs in a cell-autonomous manner.28 Cell-autonomous regulation of duodenal iron absorption in response to hypoxia has also been well documented. Early experimental evidence supported the notion that acute hypoxia affects apical iron uptake independently of systemic cues such as erythropoietic drive or hepcidin levels: increased apical iron uptake was observed in rats as early as 6 to 8 hours after initiation of hypoxia.37,38 This early induction precedes changes in circulating iron levels or erythropoiesis37,38 or a decrease in hepcidin occurring only after at least 24 hours of hypoxia in mice39 and in humans.40,41 In addition, this hypoxic response increased iron absorption but was independent of dietary or mucosal iron status.42 Although the effect of increased erythropoiesis on iron absorption has generally been attributed to the strong downregulation of hepcidin expression, a direct effect of erythropoietin (EPO) on duodenal enterocytes has been recently proposed. Srai et al43 suggested that EPO acts directly on duodenal enterocytes through its receptor EPO-R to upregulate expression of iron transporters, based on findings in a nephrectomized rat model of chronic renal failure. Whether this mechanism is relevant in human pathological conditions characterized by ineffective erythropoiesis (such as β-thalassemia), or in murine experimental models of hypoxia or anemia characterized by high erythropoietic demand and iron absorption rates, remains to be established.

While iron deficiency and hypoxia promote iron absorption, oral administration of large doses of iron attenuates the subsequent absorption of smaller doses of iron administered hours later. This effect has been attributed to decreases in transcript and protein levels of both DCYTB and DMT1, which occur as early as 6 hours post iron administration, but not to changes in the expression of FPN or HEPH.44 These findings indicate that local enterocyte iron levels can directly regulate the apical membrane phase of iron transport.

Transcriptional regulation by HIF-2

The transcriptional regulation of genes involved in apical iron uptake and mucosal iron transfer was largely unknown until the recent discovery of the involvement of HIF-2 transcription factor in this process. The HIF transcription factors are central mediators of cellular adaptation to hypoxia.45 HIF is a heterodimer, and its expression is
principally regulated by oxygen. The HIF heterodimer consists of 2 helix-loop-helix proteins: an α-regulatory subunit, which is the oxygen- and iron-responsive component, and the β-subunit, also known as the aryl hydrocarbon receptor nuclear translocator, which is constitutively expressed. Three regulatory HIF subunits have been cloned and named HIF-1α, HIF-2α, and HIF-3α. To date, HIF-1α has been the most extensively studied. In the presence of oxygen, the hydroxylation of HIF-α at conserved proline residues within the oxygen-dependent degradation domain is the rate-limiting step for subsequent HIF-α protein degradation and is catalyzed by prolyl-4-hydroxylase domain enzymes (PHDs). PHDs are iron- and 2-oxoglutarate–dependent dioxygenases utilizing O2 as a substrate, 2-oxoglutarate as a cosubstrate, and iron (Fe²⁺) and ascorbate as cofactors. The 4-hydroxyprolines are subsequently recognized by the protein von Hippel–Lindau (pVHL) E3 ubiquitin ligase, which targets HIF-α for degradation and is catalyzed by prolyl-4-hydroxylase domain enzymes (PHDs). The direct binding of HIF-2 to consensus HRE elements in the regulatory regions of the promoters has been shown for DCYTB and DMT1. At the systemic level, hepatic hepcidin is repressed, preventing its inhibitory action on duodenal iron absorption.

Figure 1. HIF-2 transcriptionally regulates the expression of key genes involved in iron transport. Under conditions of iron deficiency, hypoxia, or increased erythropoietic drive, HIF-2 is stabilized in the duodenal enterocyte and transcriptionally upregulates the expression of DMT1 + iron responsive element (IRE), DCYTB, and FPN. This leads to increased expression of DMT1 and DCYTB at the apical brush border membrane and FPN at the basal membrane. The direct binding of HIF-2 to consensus HRE elements in the regulatory regions of the promoters has been shown for DCYTB and DMT1. At the systemic level, hepatic hepcidin is repressed, preventing its inhibitory action on duodenal iron absorption.
and remains to be addressed in future studies of the role of HIF-2 in intestinal function.

The differential target gene specificity of HIF-2α vs HIF-1α in the duodenum may be due to interaction of the HIF-α N-terminal sequence with additional transcription factors, as has previously been suggested.55 Orthologs of Sp6 transcription factors may possibly act in cooperation with HIF-2 to increase iron absorption.56 Further, certain physiological features of the intestinal epithelium may explain the phenotype of HIF-2α intestinal knockout mice at the basal level. The gastrointestinal tract has a unique tissue oxygenation profile under steady-state conditions. While the epithelium is in a relatively hypoxic state, the subepithelial mucosa is highly vascularized, and meal ingestion is known to increase the mucosal blood flow. Reduced blood flow in the villus microvasculature during the fasting period could thus result in a relatively hypoxic state of the duodenal enterocytes, which would stabilize HIF-2α, therefore potentiating the expression of DMT1 and DCTYTB in order to increase apical iron uptake during digestion of a subsequent meal. Alternatively, other mechanisms could affect local HIF-2α levels in the duodenal enterocytes, such as intraluminal pH levels. In human subjects, intraluminal duodenal pH fluctuates from 4.0 during meals to below 2.0 during the fasting period. Iron absorption of inorganic iron is influenced by pH.6 Given the links between pH regulation and HIF signaling,57 it is possible that low intraluminal pH may potentiate HIF-2 stabilization. Additionally, upregulation of duodenal HIF-2α is likely to occur at the protein level through diminished PHD activity in the hypoxic microvilli. Importantly, mice developing severe anemia and tissue hypoxia in response to phenyladrazine treatment do not exhibit changes in duodenal HIF-2α mRNA levels.58 Increased duodenal HIF-2α protein stabilization has been shown to mediate the upregulation of Dmt1 and Dcytb mRNAs in mice fed an iron-deficient diet.52,53 A biphasic regulation of duodenal FPN has been reported during iron deficiency in mice, in which HIF-2 is essential in the acute regulation of iron export but dispensable in the chronic phase.29 As iron absorption rates are higher in younger animals, it is also conceivable that HIF-2 might be more important during periods of postnatal growth than in adults, HIF-2 protein levels are also stabilized in other conditions of high iron demand, such as hypoxia59 or phlebotomy78 (Figure 1). Altogether, these findings reveal an important role for HIF-2 in the iron- and oxygen-dependent regulation of iron absorption.

**Posttranscriptional regulation by the IRPs: a new IRP1/HIF-2 axis**

Posttranscriptional regulation of iron homeostasis genes in response to intracellular iron levels is mediated by IRPs, IRP1 and IRP2, which bind to IREs found in the 5′ or 3′ untranslated regions (UTRs) of target mRNAs.60 IRP1 and IRP2 protein abundance and IRE-binding activity are regulated by different mechanisms.61 IRP1 does not show detectable IRE-binding activity in the majority of tissues under physiological conditions, but rather is expressed in the form of a cytosolic aconitase. By contrast, the protein abundance of IRP2 is regulated by F-box and leucine-rich repeat protein 5, an iron- and oxygen-binding hemerythrin domainadapter protein that recruits the SKP1–CUL1–F-box E3 ubiquitin ligase complex to promote IRP2 proteasomal degradation under iron-replete conditions.62 High IRE-binding activity in response to low intracellular iron levels results in translational repression of mRNAs that contain an IRE in their 5′ UTR (such as Fpn, FltH, and FltL) or promotes mRNA stability if bound to mRNAs that contain an IRE in 3′ UTR (as in the case of Dmt1). Dmt1 is present in different isoforms, and those transcript isoforms that contain an IRE predominate in the proximal intestine. Although activation of IRPs by iron deficiency would normally be expected to repress translation of FPN, duodenal FPN levels are increased in iron-deficient animals.15 Importantly, Zhang et al63 showed that an alternative Fpn mRNA lacking the 5′ UTR IRE motif (Fpn-IRE) is preferentially expressed in the duodenum, which could explain how enterocytes circumvent repression of FPN expression by IRE/IRP machinery. Mice carrying a deletion for both IRP1 and IRP2 in the intestinal epithelium present with decreased DMT1 and transferrin receptor 1 and increased FTH and FTL protein levels, and they manifest malabsorption and villus structure disorganization associated with perinatal lethality.64 However, Irp2−/− and Irp1−/− mice are both viable but present different overt phenotypes. More specifically, mice with Irp2 deletion in the intestinal epithelium present with iron retention in the duodenal enterocytes, suggesting that IRP2 plays a cell-autonomous role in the intestine and also that IRP1 and IRP2 are partly redundant in the intestine.55,66 Furthermore, tissue-specific Irp1−/− and/or Irp2−/− knockout mouse models have demonstrated that IRP2 is the major regulator of iron homeostasis in vivo, responding to dietary iron deficiency and hypoxia.60 A 5′ UTR IRE in the Hif2α mRNA has been characterized in vitro and may serve as an additional point of HIF-2 regulation.67 Sanchez et al67 proposed that HIF-2 translation may be enhanced in the presence of adequate levels of iron. In rats, hepatic HIF-2α has been shown to be translationally repressed in response to dietary iron deficiency compatible with a role for the IRE/IRP system in this process.68

Two recent studies have demonstrated that translational regulation of HIF-2α synthesis by IRP1 in the kidney is critical for controlling erythropoiesis.69,70 Ghosh et al70 showed that Irap1−/− mice develop pulmonary hypertension and polycythemia, a phenotype that is exacerbated in response to an iron-deficient diet and is caused by excessive EPO production resulting from the absence of translational repression of Hif-2α mRNA in the kidney. Interestingly, the authors also showed that secretion of the known HIF target endothelin-1 is highly upregulated in pulmonary endothelial cells isolated from Irap1−/− mice compared with controls. Anderson et al72 further demonstrated that HIF-2 transcriptional activity is increased in the duodenum of Irap1−/− mice, as indicated by the increased mRNA expression of Dmt1+IRE, Dcytb, and Fpn mRNAs, as well as other HIF-2 target genes. Moreover, Galy et al73 recently reported that IRPs regulate apical iron uptake by controlling FPN and DMT1 through HIF-2. They further showed that IRP deficiency in the adult mouse intestinal epithelium promotes a Ft-mediated “mucosal block.”

As IRP activity is increased in the duodenum in response to iron deficiency,72 it might be hypothesized that Hif-2α is translationally repressed by IRP1. However, increased HIF-2α protein levels have been reported in the duodenum of iron-deficient mice.55 A possible explanation might be that during iron deficiency, the effects of IRP1 on Hif-2α mRNA translation are counteracted by the dominant stabilization of HIF-2α at the protein level, due to the decreased activities of PHDs (Figure 2). Moreover, IRP1 has been shown to decrease in hypoxia.73 As the duodenum is hypoxic, even at basal level, the increase in IRP1 would amplify the impact of PHD-mediated HIF regulation. By contrast, high intracellular iron would prevent the translational repression of Hif-2α by IRP1 but potentially increase the activity of PHDs (Figure 2). However, models of intestinal iron overload coupled with systemic anemia indicate that elevated iron levels do not have a pronounced effect on HIF-2 per se and that systemic anemia/hypoxia is the predominant regulator of HIF-2.74 It would be interesting to examine these hypotheses more.
specifically in mice with inducible deletion of *Irp1* or *Irp2* in the intestinal epithelium. Further studies addressing these questions may provide evidence for nonredundant roles of IRPs in the duodenum and their importance in integrating systemic physiological signals in vivo.

**HIF-2: implications for iron-related disorders**

**Inflammation**

Iron absorption is diminished during inflammatory conditions. Eventually, a decrease in serum iron limits iron availability to erythropoiesis and contributes to the anemia of inflammation (also called anemia of chronic disease [ACD]). Hypoferremia is mainly due to iron sequestration in macrophages of the reticuloendothelial system.

Hepatic hepcidin expression is markedly induced during infection and inflammation by cytokines (including interleukin [IL] 1 and IL-6), and urinary hepcidin levels are elevated in patients with chronic inflammatory diseases. IL-6 signals through binding to the IL-6 receptor and activates hepcidin transcription by binding of phosphorylated Signal Transducer and Activator of Transcription (STAT) to conserved sequence elements in the hepcidin promoter. The resulting hepcidin elevation is believed to play a major role in the pathogenesis of ACD. These features are reproducible in transgenic mouse models characterized by intestinal inflammation. However, the role of HIF-2α during intestinal inflammation has not yet been addressed. Interestingly, nitric oxide (NO), an important mediator of inflammation, has been shown to stimulate the IRE-binding activity of IRP1 in macrophages. Although this mechanism has not been validated in enterocytes, it is possible that NO–mediated translational repression of HIF-2 could contribute to the ability of inflammation to decrease in iron absorption.

**Polycythemia/ineffective erythropoiesis**

Erythrocytosis is caused by an exacerbated proliferation of erythrocyte progenitors in the bone marrow leading to an absolute increase in circulating red cell mass. Individuals who are exposed to high-altitude hypoxia develop erythrocytosis and an accompanying increase in iron absorption when compared with native residents of high altitude or to individuals living at sea level. Interestingly, HIF-2α and PHD2 polymorphisms are present at high frequencies in human populations living in the Tibetan or Andean plateaus and are associated with lower values of hemoglobin than in individuals living in other altitudes. This implies a selective advantage in these individuals in comparison with normal individuals developing polycythemia in high altitudes.
Increased but defective production of erythroblasts in the bone marrow, a process known as ineffective erythropoiesis, is a hallmark of β-thalassemia and other dyserythropoietic anemias. β-thalassemic patients and mouse models present inappropriately low expression of hepatic HIF-2α to chronic iron accumulation in humans with HH. Recently, we showed that hepatic HIF-2α expression that occurs in response to increased erythropoietic activity.54 The molecular mechanism(s) by which the erythropoietic drive promotes hepatic suppression during normal and stress erythropoiesis has not been fully elucidated so far. Possible regulators of hepcidin expression that have been proposed include changes in transferrin saturation, increased release of soluble molecules like growth differentiation factor 15 and twisted gastrulation homolog 1 from erythroblasts, and a direct effect of EPO on hepatocytes.55 Whether growth differentiation factor 15 or twisted gastrulation homolog 1 are upregulated in the gut in these conditions and whether they directly regulate iron absorption has not been examined.

Transfusion and pharmacologic chelation are the current treatments for patients with iron-loading anemias. However, both increased iron absorption and repetitive transfusions contribute to the massive organ iron load that leads to lethal complications. Anderson et al58 recently showed that intestinal HIF-2α is essential for efficient erythropoiesis. It would be of interest to explore whether intestinal HIF-2α contributes to iron absorption and iron overload observed in β-thalassemic patients.

**Hereditary hemochromatosis**

HH is an autosomal recessive genetic disorder characterized by iron overload in the liver and other parenchyma. HH is caused by mutations in genes encoding signaling molecules that regulate hepcidin expression in response to iron, namely, HFE, TIR2, and HFE2, or mutations in the hepcidin gene (HAMP) itself. The age of onset and clinical phenotype varies depending on the particular gene that is mutated.92 Another hereditary iron overload disorder (termed FPN disease) is caused by autosomal dominant mutations in the FPN gene that impair hepcidin binding or alter FPN localization.93 In regard to HFE-associated HH, different mutations have been identified; however, their penetrance is variable, and HFE homozygotes show phenotypic heterogeneity that ranges from complete absence of disease to severe iron overload in liver and pancreas leading to complications such as hepatic steatosis, hepatocellular carcinoma, and diabetes. As previously mentioned, the HIF-2α transcription factor is crucial for the regulation of iron homeostasis by regulating the expression of DMT1 and DCYTB in the duodenum.52 Moreover, HIF-2α stabilization in the intestinal epithelium is sufficient to augment expression levels of DMT1, DCYTB, and FPN and leads to hepatic iron overload.29,53 As previously mentioned, high expression levels of duodenal Dmt1, DcytB, and Fpn mRNA correlate with high iron absorption rates in various models characterized by low hepcidin expression. Importantly, deletion of intestinal Hif-2α in hepatic knockout mice alleviates iron overload in the liver and pancreas by decreasing the expression of the duodenal DMT1, DCYTB, and FPN.34 These findings highlight the importance of HIF-2α in the transcriptional upregulation of genes involved in iron absorption in the context of hepcidin deficiency and suggest that HIF-2α could contribute to chronic iron accumulation in humans with HH. Recently, we showed that hepatic HIF-2α is dispensable for the homeostatic response to iron deficiency, but genetic stabilization of HIF-2α due to hepatic loss of VHL mediates a radical decrease in hepatic expression that occurs in response to increased erythropoietic activity.54 Moreover, hepatic HIF-2α stabilization in the context of VHL deficiency leads to the development of hepatic steatosis and highly angiogenic tumors in mice. It has been previously proposed that DMT1 and DCYTB,96 2 HIF-2α target genes, could act as genetic modifiers in HFE hemochromatosis. Therefore, whether polymorphic variation in HIF-2α itself contributes to the phenotypic heterogeneity of HFE-related hemochromatosis patients developing severe clinical features (steatosis and cancer) vs milder phenotypes would be of interest.

**Potential of the use of HIF-2 modulators in the treatment of iron-related diseases**

Although the role of HIF-2α in the pathogenesis of HFE or other forms of hemochromatosis in humans remains to be established, the previously discussed findings provide proof of concept that HIF-2α inhibitors could be employed therapeutically in patients with HH in combination with conventional phlebotomy. Increased iron absorption is also believed to contribute to iron loading in thalassemias and sideroblastic anemia, in addition to that caused by successive blood transfusions. Therefore, HIF-2α inhibitors might also prove beneficial for these patients by inhibiting both inefficient erythropoiesis and iron absorption. Currently, 1 study has identified a class of chemical compounds that inhibit HIF-2α translation by an IRP1-dependent mechanism,97 but the pharmacokinetic properties and inhibitory potential of these compounds in vivo have not yet been determined. The recent demonstration of the critical role of the IRP–HIF-2 axis in intestinal iron absorption69,70 may encourage the evaluation of these HIF-2α inhibitors in vivo.

Finally, prolyl-hydroxylase inhibitors (PHIs) represent a promising potential alternative treatment for anemia.98 PHIs might be particularly advantageous in patients with anemia of renal failure, who are currently treated with intravenous/subcutaneous injections of recombinant EPO or related erythropoiesis-stimulating agents. PHIs improved hematologic parameters in a mouse model of chronic renal insufficiency by inducing hepatic Epo expression.100 However, the safety profile of PHIs and their ultimate efficacy in inducing the stabilization of both HIF-1 and HIF-2 in patients remain to be determined. Given the dual roles of HIF-2 in the regulation of iron absorption and EPO expression, PHIs or other compounds that specifically stabilize HIF-2α may represent possible therapeutic strategies for patients with iron-deficiency anemia or ACD.

**Acknowledgments**

The authors thank Sophie Vaulont (Institut Cochin) and Karin Finberg (Duke University) for critical reading of the manuscript.

**Authorship**

Contribution: M.M., P.M., and C.P. contributed to the writing of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for M.M. is Centre for Stem Cells & Regenerative Medicine, Division of Genetics & Molecular Medicine, King’s College London School of Medicine, London, United Kingdom.

The current affiliation for P.M. is Department of Pharmacology and Cancer Biology, Duke University, Duke University Medical Center, Durham, NC.

Correspondence: Carole Peyssonnaux, INSERM, U1016, Institut Cochin, Faculté de Médecine Cochin Port Royal, 24, rue du Faubourg Saint Jacques, Paris, 75014, France; e-mail: carole.peyssonnaux@inserm.fr.
References


